Shao H, et al. - Given that guidelines on standard diabetes care recommend that glycemic treatment goals for older adults consider complications and life expectancy of the patient, researchers used data from the 2011 to 2016 National Health and Nutrition Examination Survey (NHANES) to study the impact of diabetes complications and associated life expectancies on the cost-effectiveness (CE) of HbA_1c treatment goals. For this investigation, they generated nationally representative subgroups of older people with diabetes with various health states. On average, a stringent goal was cost-effective for non-complicated people ($10,007 per QALY) or microvascular complications only (excluding renal failure; $19,621 per QALY), but not cost-effective for people with one or more macrovascular complications (all >$82,413 per QALY). In addition, when an individual had less than 7 years of life remaining, a stringent objective was not cost-effective. The results support the suggestion from the guideline that glycemic objectives for older adults should consider the complexity of their complications and their life expectancy from a CE view.